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Viral vectors are efficient gene delivery systems, although most of these vectors still
present limitations to their practical use, such as achieving only transient transgene
expression and a risk of insertional mutations. We have recently developed an RNA
virus-based episomal vector (REVec), based on nuclear-replicating Borna disease virus
(BoDV). REVec can transduce transgenes into various types of cells and stably express
transgenes; however, an obstacle to the practical use of REVec is the lack of a
mechanism to turn off transgene expression once REVec is transduced. Here, we
developed a novel REVec system, REVec-L2b9, in which transgene expression can
be switched on and off by using a theophylline-dependent self-cleaving riboswitch.
Transgene expression from REVec-L2b9 was suppressed in the absence of theophylline
and induced by theophylline administration. Conversely, transgene expression from
REVec-L2b9 was switched off by removing theophylline. To our knowledge, REVec-
L2b9 is the first nuclear-replicating RNA virus vector capable of switching transgene
expression on and off as needed, which will expand the potential for gene therapies by
increasing safety and usability.
Keywords: Borna disease virus, virus vector, riboswitch, expression control, safety
INTRODUCTION
Increasing lists of causative genes for genetic disorders and gene delivery systems have led to the
development of gene therapies over several decades. In particular, the development of efficient
and safe gene delivery systems is critical to introduce genes to treat genetic disorders. To date,
various non-viral gene delivery systems, such as cationic liposome technology (Miller, 1998),
and viral delivery systems, such as adeno virus-, adeno-associated virus (AAV)-, and lentivirus-
based vectors, have been developed (Escors and Breckpot, 2010; Crystal, 2014; Naso et al., 2017).
Although these systems can be used to successfully transduce a gene of interest, they still present
disadvantages such as achieving only transient expression of transgenes, cytotoxicity, and the
potential for integration of viral vector sequences into the host genome. Moreover, to maximize
the effect of transgenes, transgene expression should be controlled at an appropriate level and with
appropriate timing. Thus, possible requirements for an ideal gene delivery system include long-
term expression of transgenes, minimal cytotoxicity, reduction of integration risk, and controllable
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expression of transgenes. However, none of the delivery systems
described above meet all of these requirements at present.
Recently, oncolytic virus therapy has been increasingly
appreciated as a promising and realistic approach for treating
cancer. For example, herpes simplex virus type 1, vaccinia virus,
adenovirus, and reovirus are major oncolytic viruses undergoing
clinical trials (Hu et al., 2006; Ramesh et al., 2006; Vidal et al.,
2006; Parato et al., 2012). To increase the oncolytic activity of
these viral therapies, the viruses are often genetically engineered,
such as through the insertion of human granulocyte macrophage
colony-stimulating factor (GM-CSF) (Hu et al., 2006). Because
these modifications may harm the host, the use of viral vectors,
in which the expression of transgenes can be controlled, will be a
safer therapeutic option.
In previous studies, we established a Borna disease virus
(BoDV)-based vector, the RNA virus-based episomal vector
(REVec) system (Daito et al., 2011). BoDV is a non-segmented,
negative strand RNA virus that exhibits several unique biological
characteristics. For example, BoDV replicates in the nucleus
without overt cytopathic effects (Ludwig and Bode, 2000).
Furthermore, the ribonucleoprotein complex (RNP) of BoDV
interacts with the host chromosome (Matsumoto et al., 2012),
which enables stable persistent infection in the nucleus. Although
integrations of BoDV sequences to the host genome have been
reported (Horie et al., 2010), the probability is extremely low
(Horie et al., 2013). These characteristics indicate that BoDV
could be an ideal RNA viral vector for safe, efficient, and
long-term transgene expression. The REVec system expresses
transgenes from an additional transcription cassette in the BoDV
genome between the phosphoprotein (P) and matrix (M) genes
(Daito et al., 2011). REVec carrying the GFP gene, REVec-GFP,
achieved long-term expression of GFP in both cultured cells
and mouse brains (Daito et al., 2011). We have also reported
that REVec can express arbitrary miRNAs and silence their
target genes (Honda et al., 2016). Moreover, REVec can be
efficiently transduced in human pluripotent stem cells (iPSCs)
without disturbing the pluripotency of the cells (Ikeda et al., 2016;
Komatsu et al., 2019). Recently, we developed a REVec system
lacking both the M and glycoprotein (G) genes, REVec1MG
(Fujino et al., 2017). REVec1MG seems to be safer than the
original REVec because REVec1MG does not express the M and
G proteins, which are required for viral particle production and
transmission and may induce cytotoxicity (Cathomen et al., 1998;
Bajramovic et al., 2003; Honda et al., 2009). Although the REVec
system is a unique and safe RNA viral vector, one concern about
the system is the lack of a mechanism for regulating transgene
expression from REVec in transduced cells. Therefore, it is
important to develop a version of REVec capable of controlling
transgenes for practical use.
Riboswitches are ligand-binding RNA structures that serve as
molecular switches (Serganov and Nudler, 2013). Riboswitches
can modulate transcription, translation, splicing and mRNA
stability in bacteria and eukaryotes. For example, in different
groups of eukaryotes, thiamine pyrophosphate riboswitches
regulate genes by alternative splicing in filamentous fungi (Cheah
et al., 2007), regulate premature translation termination in green
algae (Croft et al., 2007), and regulate splicing and mRNA
degradation in higher plants (Bocobza et al., 2007; Wachter
et al., 2007). Based on the natural riboswitch mechanism,
various synthetic riboswitches have been developed, such as a
tetracycline-dependent translational riboswitch in yeast (Berens
et al., 2001; Suess et al., 2003). The cis-acting self-cleaving
riboswitch L2bulge9 (L2b9) is an “ON” riboswitch consisting of
a theophylline-dependent aptamer and a self-cleaving ribozyme
(Figure 1A; Win and Smolke, 2007). When theophylline is
unbound to the aptamer domain, the self-cleaving domain
is in an active form, which cleaves itself and causes mRNA
degradation. On the other hand, when theophylline binds to the
aptamer domain, the ribozyme domain shifts to an inactive form,
which blocks ribozyme cleavage, stabilizing mRNA and restoring
mRNA translation. Since this riboswitch has been confirmed to
function in mammalian cells, we reasoned that a novel REVec
system capable of controlling transgene expression could be
developed using the L2b9 riboswitch.
In this study, we generated a novel RNA viral vector,
REVec-L2b9, capable of controlling transgene expression using
a theophylline-dependent self-cleaving riboswitch. Transgene
expression from REVec-L2b9 was successfully suppressed in the
absence of theophylline and was induced by theophylline in a
dose-dependent manner. Notably, removal of theophylline re-
suppressed transgene expression, demonstrating that transgene
expression from REVec-L2b9 can be controlled as needed.
MATERIALS AND METHODS
Cells
Puromycin-resistant Vero cells (a monkey kidney cell line)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Nacalai Tesque, Kyoto, Japan) supplemented with 2% fetal calf
serum (FCS). 293T cells (a human embryonic kidney cell line)
were cultured in DMEM supplemented with 10% FCS.
Plasmids
The REVec plasmid harboring an extra transcription cassette,
pBoDV, was generated as described previously (Daito et al.,
2011). The self-cleaving riboswitch L2bulge9 (L2b9), described
previously (Win and Smolke, 2007), was synthetized by PCR
with the appropriate primers (Supplementary Table S1).
The Gaussia Luciferase (GLuc) gene was subcloned upstream
of L2b9 (GLuc-L2b9x1) and L2b9 tandem repeats (GLuc-
L2b9x2 and GLuc-L2b9x3). pBoDV-GLuc-L2b9x1, pBoDV-
GLuc-L2b9x2 and pBoDV-GLuc-L2b9x3 were generated by the
insertion of GLuc-L2b9 sequences into the BstBI and PacI sites
of pBoDV. The Ras-related C3 botulinus toxin substrate 1 (Rac1,
GenBank: AF498964.1) gene was cloned from the cDNA of
293T cells. The constitutively active form of Rac1 (RacQ61L)
was generated by site-directed mutagenesis. pBoDV-RacQ61L-
L2b9x2 was generated by the insertion of the RacQ61L sequence
into the BstBI and Sbf1 sites of pBoDV-GLuc-L2b9x2.
Reverse Genetics of REVec
Recombinant viruses were generated with reverse genetics
technology established by our group (Daito et al., 2011). 293T
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FIGURE 1 | Generation of REVec capable of controlling transgene expression. (A) Schematic diagram of L2b9. (B) Representation of the REVec-Gluc-L2b9 vector
genomes. (C) IFA of established REVec-L2b9-infected Vero cells. Bars, 10 µm. (D) N protein expression in established REVec-L2b9-infected cells. Lysates of
REVec-L2b9-infected cells were subjected to western blotting using anti-N, anti-tubulin, and anti-GFP antibodies. (E) RT-PCR of the L2b9 cassette in REVec-L2b9.
Copies of GLuc-L2b9 in each established REVec-L2b9 vector were detected by RT-PCR. (F) Growth kinetics of REVec-GFP, REVec-GLuc, and REVec-GLuc-L2b9s.
Vero cells were de novo infected with REVecs at an MOI of 0.01, and the viral growth rate was monitored by IFA.
cells were transfected with these BoDV-expressing plasmids
and the helper plasmids expressing the BoDV N, P, and L
genes using Lipofectamine R© 2000 (Thermo Fisher Scientific,
Waltham, MA, United States). At 3 days post-transfection,
the transfected 293T cells, which were REVec-producing cells,
were passaged. One day after the first passage, puromycin-
resistant Vero cells were overlaid and co-cultured with
the REVec-producing 293T cells to propagate REVec by
the cell-to-cell transmission between 293T and Vero cells.
Then, the cells were passaged every 3 days in the presence
of puromycin to remove the transfected 293T cells. After
several weeks of the culture, we finally obtained REVec-
infected Vero cells. The resulting REVecs were REVec-
GFP, REVec-GLuc, REVec-GLuc-L2b9x1, REVec-GLuc-L2b9x2,
REVec-GLuc-L2b9x3, REVec-RacQ61L, and REVec-RacQ61L-
L2b9x2. The established REVec-infected Vero cells were
evaluated for BoDV proteins by immunofluorescence assay
(IFA) and western blotting to confirm REVec production
and used for most of the experiments except for de novo
infection experiments.
Frontiers in Microbiology | www.frontiersin.org 3 November 2019 | Volume 10 | Article 2485
fmicb-10-02485 November 4, 2019 Time: 15:40 # 4
Yamamoto et al. BoDV Vector With a Riboswitch
Virus Preparation
REVec-infected Vero cells were collected and washed with
phosphate-buffered saline (PBS). The cells were sonicated in
DMEM supplemented with 2% FCS and then the samples
were centrifuged to remove cell debris. After centrifugation, the
supernatants were collected as virus stocks.
De novo Virus Infection
Vero cells were infected with REVecs at a multiplicity of infection
(MOI) of 0.01 at 37◦C. After viral absorption for 1 h, the cells were
washed with PBS and passaged every 3 days. Virus propagation
was detected by IFA.
IFA
Immunofluorescence assay was conducted as described
previously (Kojima et al., 2014) with some modifications.
Briefly, cells were fixed for 20 min in 4% paraformaldehyde
and permeabilized by incubation in PBS containing 0.25%
Triton X-100 for 10 min. After permeabilization, the cells
were incubated with a rabbit anti-BoDV P antibody for 1 h.
This was followed by incubation with the appropriate Alexa
Fluor-conjugated secondary antibodies (Invitrogen, Carlsbad,
CA, United States). The cells were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI). REVec-GLuc-L2b9x2-,
REVec-RacQ61L-L2b9x2-, and REVec-RacQ61L-infected Vero
cells were incubated with a rabbit anti-P antibody for 1 h.
This was followed by incubation with Acti-stain 488 phalloidin
(Cytoskeleton Inc., Denver, CO, United States), DAPI and
the appropriate Alexa Fluor-conjugated secondary antibody
for 1 h. An ECLIPSE Ti confocal laser-scanning microscope
(Nikon, Shinagawa, Japan) was used for cell immunofluorescence
imaging and data collection.
Luciferase Assay
Theophylline (Wako, Osaka, Japan) was dissolved in DMEM
supplemented with 2% FCS. REVec-GLuc-infected Vero cells
(4 × 104/well) were seeded into 48-well plates. At 3 h after
seeding, the cells were treated with 0, 1, 3, or 10 mM theophylline.
After 24 h of incubation, the luciferase activity in the culture
medium was measured using a Lumat LB 9507 luminometer
(Berthold, Bad WildBad, Germany) and a BioLux Gaussia
Luciferase Assay Kit (New England Biolabs, Ipswich, MA,
United States) according to the manufacturer’s instructions. The
cells were counted with a hemocytometer, and luciferase activities
were normalized by the cell counts.
Western Blot Analysis
Vero cells infected with REVec were lysed with SDS sample
buffer. The total cell lysate was subjected to SDS-PAGE and
transferred to a PVDF membrane. The membranes were
then blocked and incubated with the primary antibodies.
The antibodies used in this study were as follows: mouse
anti-BoDV N (HN132), mouse anti-GFP (Takara Bio Inc.,
Shiga, Japan) and mouse anti-Tubulin (Sigma-Aldrich, St.
Louis, MO, United States) antibodies. After three washes with
0.05% Tween 20 in Tris-buffered saline (TBS), horseradish
peroxidase-conjugated secondary antibodies (Invitrogen,
Waltham, MA, United States) were applied for 1 h at room
temperature. The bound antibodies were detected using an ECL
Prime Western Blotting System (GE Healthcare Bioscience,
Piscataway, NJ, United States) and a FUJIFILM LAS-4000 Mini
Lumino Image analyzer (Fujifilm, Tokyo, Japan).
RNA Preparation and Real-Time RT-PCR
Total RNA was extracted from the REVec-infected cells using
TRIzol (Life Technologies, Grand Island, NY, United States) and
reverse transcribed with a Verso cDNA Synthesis Kit (Thermo
Fisher Scientific, Waltham, MA, United States) using the primers
shown in Supplementary Table S1. qRT-PCR assays of REVec
genomic and antigenomic RNA were carried out using a gene-
specific double fluorescence-labeled probe and THUNDERBIRD
Probe qPCR Mix or THUNDERBIRD SYBR qPCR Mix (Toyobo,
Osaka, Japan) in a Rotor Gene Q 2plex HRM system (Qiagen,
Hilden, Germany). The primers and probe used are shown in
Supplementary Table S1.
RESULTS
Generation of REVec Capable of
Controlling the Expression of a
Transgene
To develop a version of REVec capable of controlling transgene
expression in vector-transduced cells, we generated pBoDV
plasmids harboring one to three copies of L2b9, a theophylline-
dependent self-cleaving riboswitch, in the 3′ UTR of the Gaussia
luciferase (GLuc) gene, inserted between the P and M genes
of the BoDV genome (Figure 1B). Using these plasmids, we
generated REVecs (REVec-GLuc-L2b9x1, REVec-GLuc-L2b9x2,
and REVec-GLuc-L2b9x3) via a reverse genetics approach
established previously (Daito et al., 2011). We successfully
obtained Vero cells infected with REVec-GLuc-L2b9x1, REVec-
GLuc-L2b9x2, and REVec-GLuc-L2b9x3 (Figures 1C,D). We
confirmed that the repeats of the L2b9 sequence were retained
in the vector genome after establishing REVec-infected Vero
cells (Figure 1E). Although REVec-GLuc-L2b9s contained the
L2b9 ribozyme sequence in the REVec antigenomic RNAs, the
replication kinetics of REVec-GLuc-L2b9s were comparable to
those of REVec-GFP and REVec-GLuc during the de novo
infection (Figure 1F). These results indicate that the insertion of
the L2b9 sequence in REVec antigenomic RNA does not induce
any deleterious effects on vector replication in the infected cells.
Induction of Transgene Expression From
REVec-GLuc-L2b9 by Theophylline
We then assessed whether the administration of theophylline
could induce luciferase expression in cells infected with REVec-
GLuc-L2b9s. As shown in Figure 2A, in the absence of
theophylline, the luciferase activities derived from REVec-GLuc-
L2b9-infected cells were reduced with an increase in the number
of the L2b9 sequences, indicating that the L2b9 sequence
suppresses luciferase expression. When theophylline was added
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FIGURE 2 | Induction of transgene expression from REVec-GLuc-L2b9 by theophylline. (A) Relative luciferase activity after 24 h of treatment with 0, 1, 3, and 10 mM
theophylline. Luciferase activities were normalized by the cell counts. (B,C) Quantification of RNA expression in REVec-GLuc-L2b9-infected Vero cells by qRT-PCR.
The amounts of GLuc mRNA (B) and REVec antigenomic RNA (C) were measured and standardized against that of REVec genomic RNA. Values are expressed as
the mean ± S.E. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.005; ∗∗∗∗P < 0.001 (Student’s t-test). At least three experiments were performed.
to the cells, luciferase expression was induced in a dose-
dependent manner (Figure 2A). To evaluate whether the increase
in luciferase activity induced by theophylline in REVec-GLuc-
L2b9-infected cells resulted from mRNA stabilization of GLuc,
we evaluated the amount of GLuc mRNA in the presence or
absence of theophylline. As shown in Figure 2B, the amount
of GLuc mRNA per REVec genomic RNA was increased by the
administration of theophylline. On the other hand, the amount
of REVec antigenome RNA per REVec genomic RNA was
unaffected at all tested theophylline concentrations (Figure 2C).
These results demonstrate that theophylline administration can
induce transgene expression from REVec-L2b9 by stabilizing
transgene mRNAs, as expected.
Reversible Control of Transgene
Expression From REVec-GLuc-L2b9 by
Theophylline
We next evaluated whether the theophylline-induced luciferase
expression from REVec-GLuc-L2b9 returns to the basal level
after cessation of the treatment. We treated REVec-GLuc-L2b9-
infected cells with theophylline for 1 day, subsequently washed
the cells, and cultured the cells in the absence of theophylline for
one additional day (Figure 3A). As shown in Figure 3B, luciferase
activity was induced by theophylline treatment (Day 1) and
returned to the basal level after the removal of theophylline (Day
2), demonstrating that transgene expression from REVec-L2b9
can be switched on and off by theophylline as needed.
Control of Cell Morphology Using the
REVec-L2b9 System
Finally, we evaluated whether our system is effective enough
to function in biological contexts. To this end, we tried
to modulate cell morphology using the REVec-L2b9 system.
Rac1 (Ras-related C3 botulinus toxin substrate 1) is a small
GTPase that regulates various biological processes, including cell
membrane ruffling (Hall, 1998). A constitutively active mutant
of Rac1, RacQ61L, induces cell membrane ruffling and bubble-
like structures (Zhang et al., 1999; Davis et al., 2013). To
regulate cell membrane ruffling as needed, we inserted RacQ61L
into the pBoDV-L2b9x2 plasmid, generated REVec-RacQ61L-
L2b9x2 (Supplementary Figure S1), and established REVec-
transduced Vero cells by reverse genetics. In the absence of
theophylline, REVec-RacQ61L-transduced Vero cells exhibited
marked membrane ruffling, whereas REVec-GLuc-L2b9x2- and
REVec-RacQ61L-L2b9x2-transduced cells showed less ruffling
(Figures 4A,B). When theophylline was added, membrane
ruffling was induced in REVec-RacQ61L-L2b9x2-transduced
cells, while that in REVec-RacQ61L- and REVec-GLuc-L2b9x2-
transduced cells was not affected (Figures 4A,B). These results
indicate that the expression of RacQ61L from REVec-RacQ61L-
L2b9x2 is induced by theophylline administration, which triggers
membrane ruffling in the transduced cells. Again, the levels
of REVec antigenome RNAs were unchanged by theophylline
administration (Supplementary Figure S2), confirming that this
control is specific to the expression of the L2b9-containing
transgene from REVec. We then evaluated whether theophylline-
induced membrane ruffling disappears after the cessation
of theophylline treatment. To this end, we treated REVec-
transduced Vero cells with theophylline for 1 day and then ceased
the treatment, as shown in Figure 4C. The theophylline-induced
membrane ruffling of REVec-RacQ61L-L2b9x2-transduced cells
decreased within 1 day after the cessation of treatment
(Figure 4D). On the other hand, the membrane ruffling
of REVec-RacQ61L- and REVec-GLuc-L2b9x2-transduced cells
was comparable regardless of the presence of theophylline
(Figure 4D). These results demonstrate that the REVec-L2b9
system is effective enough to modulate a biological process.
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FIGURE 3 | Reversible control of transgene expression from REVec-GLuc-L2b9 by theophylline. (A) Time course of switching off the expression from
REVec-GLuc-L2b9. Theophylline treatment was ceased on Day 1. The culture media were collected at the indicated time points, and luciferase activity was
measured. (B) Relative luciferase activity at Days 1 and 2. Theophylline treatment at the indicated concentration was ceased on Day 1. Luciferase activities were
normalized by the cell counts. Values are expressed as the mean ± S.E. ∗P < 0.05; ∗∗∗P < 0.005; ∗∗∗∗P < 0.001; n.s., no significance (Student’s t-test; vs. 0 mM).
At least three experiments were performed.
FIGURE 4 | Control of cell morphology using the REVec-L2b9 system. (A) IFA of Vero cells infected with REVec-GLuc-L2b9x2, REVec-RacQ61L-L2b9x2, and
REVec-RacQ61L. Cells were incubated with or without 3 mM theophylline for 1 day. Bars, 10 µm. (B) The percentages of ruffled cells. Cells were incubated with
3 mM theophylline for 1 day, and cell morphology was observed by IFA. (C) Time course of switching off the expression from REVec-RacQ61L-L2b9x2. Cells were
incubated with 3 mM theophylline for 1 day, and then theophylline treatment was ceased on Day 1. (D) The percentages of ruffled cells on Days 1 and 2.
Theophylline treatment was ceased on Day 1. Cell morphology was observed by IFA. Values are expressed as the mean ± S.E. ∗∗∗∗P < 0.001; n.s., no significance
(Student’s t-test). At least three experiments were performed.
DISCUSSION
Viral vector systems are widely used not only in basic researches
but also in gene and cellular therapies. Although viral vectors
based on lentiviruses/retroviruses, adenoviruses and AAVs are
commonly chosen in clinical studies and applications at present,
these vectors still present some disadvantages. For instance,
adenovirus vectors induce cytopathic effects and immune
responses (Franklin et al., 1999; Muruve, 2004). Integrating viral
vectors, such as lentivirus vectors, cause insertional mutagenesis
and oncogenesis (Schambach et al., 2013). Transgene expression
from AAV vector is transient because of the loss of AAV vector
genomes in dividing tissues (Colella et al., 2018). On the other
hand, RNA virus vectors, including vesicular stomatitis virus
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(VSV) and Sendai virus vectors, are safer than lentivirus and
DNA virus vectors since they present a lower risk of viral genome
integration into the host genome. However, most RNA virus
vectors cannot transduce transgenes for a long period of time due
to virus extinction, which is a weakness of these vectors.
REVec is unique among RNA virus vectors because it can
establish long-lasting persistent infection in the nucleus as
an episomal RNA associated with the cellular chromosomes,
supporting long-term expression of transgenes. Therefore,
REVec is an ideal virus vector for safe and long-term gene
delivery. Although REVec is ideal for long-term gene delivery,
sustained transgene expression cannot be turned off once REVec
is transduced. T-705 is a candidate chemical that can eliminate
REVec from the transduced cells in the case of adverse reactions
from sustained transgene expression (Tokunaga et al., 2017).
However, if T-705 eliminates REVec from the transduced cells
in such cases, re-transduction of the vector is required for the
re-expression of transgenes. To further increase the safety and
usefulness of REVec, a vector capable of controlling transgene
expression would be ideal. Additionally, the activation and
silencing of therapeutic transgenes will be critical to moderate
recurrent symptoms of chronic diseases, such as epilepsy
(Weinberg and McCown, 2013), in a timely manner and to
avoid side effects due to sustained overexpression of transgenes.
Viral vectors in which a transgene is repressed by constant
administration of substances, such as antibiotics, may cause
potential clinical problems. Therefore, the use of transgene-
inducible systems that can reversibly induce transient transgene
expression may be the best option for obtaining a safer and useful
therapeutic tool.
Among the existing gene regulatory systems, the tetracycline
(Tet)-dependent transcriptional switch is the most widely
exploited system for controlling transgene expression.
The Tet regulatory system has been encoded within AAVs
(McGee Sanftner et al., 2001), high-capacity helper-dependent
adenoviruses (Salucci et al., 2002), lentiviruses (Kafri et al., 2000;
Johansen et al., 2002; Régulier et al., 2002) and retroviruses (Iida
et al., 1996), achieving successful gene regulation. However,
because non-retroviral RNA viruses, including REVec, replicate
without a known DNA intermediate stage, transcriptional
regulation using Tet is not applicable to the RNA virus vector
systems. To regulate transgene expression from REVec, we
therefore sought to apply an RNA-based regulatory system:
a riboswitch.
Although a self-cleaving riboswitch in the genomic or
antigenomic RNA of RNA viruses seems to be deleterious to
their replication, several studies have succeeded the application
of a self-cleaving riboswitch to the engineering of cytoplasmic-
replicating RNA viruses thus far (Ketzer et al., 2014; Bell
et al., 2015; Takahashi and Yokobayashi, 2019). In the case
of a vector based on an alphavirus (a positive-stranded RNA
virus) with a theophylline-dependent self-cleaving riboswitch,
theophylline is required for stabilizing the virus genome
and generating the vector (Bell et al., 2015), consistent with
our concern. Because transgene mRNA synthesis coincides
with alphavirus replicon replication, switching off transgene
expression results in the extinction of the vector. In contrast,
we successfully rescued REVec-L2b9 regardless of theophylline
administration. Furthermore, the induction of transgene
expression from REVec-L2b9 by theophylline was shown
to be reversible (Figures 2A, 3B, 4B,D), while the amount
of the vector was not affected by theophylline (Figure 2C
and Supplementary Figure S2). This may have occurred
because, unlike alphavirus vector, which contains a positive-
strand RNA genome, newly synthesized REVec antigenomic
RNA molecules are co-transcriptionally packaged by the
N protein into RNP (Honda and Tomonaga, 2013), which
prevents the antigenomic RNA from undergoing self-cleavage
by the riboswitch.
REVec-L2b9 has several advantages over the reported
cytoplasmic-replicating RNA virus vector systems using
riboswitches. Among the reported systems (Ketzer et al., 2014;
Bell et al., 2015; Takahashi and Yokobayashi, 2019), only REVec
and VSV-based vectors have been evaluated to control the
transgene expression by riboswitches without affecting the vector
replication. REVec-L2b9 induced the transgene expression
within 24 h (Figure 2A), while the VSV-based systems took
48 h (Takahashi and Yokobayashi, 2019). This suggests that
the transgene induction from REVec-L2b9 might be faster
than that from the VSV-based systems. Additionally, REVec
has an advantage in long-term transduction of transgenes,
since the transgene expression of the VSV-based vectors is
generally transient, while REVec has been reported to express the
transgene for at least 8 months (Daito et al., 2011). Furthermore,
we demonstrated for the first time that REVec-L2b9 could
control a biological process (Figure 4), whereas only regulation
of reporter gene expressions was evaluated in the VSV-based
systems (Takahashi and Yokobayashi, 2019).
The ratio of transgene expression in the “ON” state to
the “OFF” state obtained in this study might not be high
enough for the practical use of REVec-L2b9. To solve this
problem, we sought to increase the number of the L2b9
sequences in the transgene mRNA. With the increase in
the L2b9 sequences, the amount of transgene expression in
the “OFF” state was decreased as expected (Figure 2A and
Supplementary Figure S3A). This result indicates that REVec
carrying more L2b9 sequences reduces the risk of unexpected
consequences caused by sustained transgene expression. In
contrast to the “OFF” state, transgene expression in the
“ON” state was comparable regardless of the number of
riboswitches (Supplementary Figure S3B). Improvement of
transgene silencing in the “OFF” state and transgene expression
in the “ON” state by optimizing the aptamer-ribozyme and
aptamer-compound sets will further increase the safety and
usefulness of the REVec system.
In conclusion, to our knowledge, this is the first study to
develop a nuclear-replicating RNA virus vector whose transgene
expression can be switched on and off at any time point
as needed. REVec-L2b9 is a safe and useful system for gene
delivery, although some improvements can be introduced for
future practical applications. For example, we used transmission-
competent REVec as a platform for this proof-of-concept
study because of easy preparation and handling. However, it
is expected to be safer if we introduce the L2b9 riboswitch
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to transmission-defective REVec1MG (Fujino et al., 2017).
Additionally, REVec still presents some disadvantages: i.e., it
takes a long time to generate recombinant viral vectors and the
vector yield is not high. By improving the efficiency of vector
preparation and transgene expression control, REVec-L2b9 will
become a remarkable option for safer gene and cellular therapies
with a fail-safe switch for transgene expression in vivo.
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